TABLE 1.
Glycan no. | Glycan | MFI for: |
|||
---|---|---|---|---|---|
Array 1 | Array 2 | Array 3 | Avg | ||
1 | β-Glc-Sp | 156.625 | 376.875 | 413.625 | 315.708 |
2 | β-Gal-Sp | 271.125 | 313.75 | 347.75 | 310.875 |
3 | α-Man-Sp | 133.5 | 160.625 | 157.375 | 150.5 |
4 | α-Fuc-Sp | 180.375 | 327.125 | 307 | 271.5 |
5 | α-Rha-Sp | 163.625 | 135.375 | 115.375 | 138.125 |
6 | β-GlcNAc-Sp | 505.125 | 441.875 | 429 | 458.666 |
7 | β-GalNAc-Sp | 512.875 | 345.125 | 360.875 | 406.291 |
8 | Tobramycin | 485.25 | 449.75 | 432.375 | 455.791 |
9 | Gal-β-1,3-GlcNAc-β-Sp | 250 | 225.375 | 203.75 | 226.375 |
10 | Gal-α-1,3-Gal-β-1,3-GlcNAc-β-Sp | 187.125 | 375.625 | 337.5 | 300.083 |
11 | Neu5Ac-α-2,3-Gal-β-1,3-GlcNAc-β-Sp | 157.75 | 186 | 140.875 | 161.541 |
12 | Neu5Ac-α-2,6-Gal-β-1,3-GlcNAc-β-Sp | 10.625 | 57.375 | 55.75 | 41.25 |
13 | Neu5Gc-α-2,3-Gal-β-1,3-GlcNAc-β-Sp | 20 | 34 | 21.5 | 25.166 |
14 | Neu5Gc-α-2,6-Gal-β-1,3-GlcNAc-β-Sp | 19.375 | 63.25 | 72.5 | 51.708 |
15 | Neu5Gc-α-2,6-Gal-β-1,3-GlcNAc-β-Sp | 9 | 105.5 | 38 | 50.833 |
16 | Gal-β-1,4-Glc-β-Sp | 17 | 104.75 | 64 | 61.916 |
17 | Gal-α-1,3-Gal-β-1,4-Glc-β-Sp | 26.25 | 89.875 | 63.875 | 60 |
18 | Gal-α-1,4-Gal-β-1,4-Glc-β-Sp | 62.125 | 128 | 68.125 | 86.083 |
19 | GlcNAc-β-1,3-Gal-β-1,4-Glc-β-Sp | 5 | 76.625 | 62.375 | 48 |
20 | GalNAc-β-1,3-Gal-β-1,4-Glc-β-Sp | 148.375 | 168.375 | 161 | 159.25 |
21 | Neu5Ac-α-2,3-Gal-β-1,4-Glc-β-Sp | 75 | 79 | 61.875 | 71.958 |
22 | Neu5Ac-α-2,6-Gal-β-1,4-Glc-β-Sp | 71.625 | 46.75 | 59.375 | 59.25 |
23 | Neu5Gc-α-2,3-Gal-β-1,4-Glc-β-Sp | 6.5 | 80.125 | 116.125 | 67.583 |
24 | Neu5Ac-α-2,6-Gal-β-1,4-Glc-β-Sp | 59.75 | 84.25 | 110.5 | 84.833 |
25 | Gal-β-1,4-(Fuc-α-1,3)-Glc-β-Sp | 149.25 | 121.25 | 177.875 | 149.458 |
26 | GalNAc-β-1,3-Gal-α-1,4-Gal-β-1,4-Glc-β-Sp | 49 | 48.5 | 22.75 | 40.083 |
27 | GlcNAc-β-1,6-GlcNAc-β-Sp | 73.625 | 114.375 | 117.875 | 101.958 |
28 | 4-P-GlcNAc-β-1,4-Man-β-Sp | 108 | 202.5 | 138.625 | 149.708 |
29 | Glc-α-1,2-Gal-α-1,3-Glc-α-Sp | 143.5 | 94.25 | 88.25 | 108.667 |
30 | Gal-β-1,3-GalNAc-α-Sp | 36.75 | 35.875 | 38 | 36.875 |
31 | Gal-β-1,4-GlcNAc-β-Sp | 6.125 | 40.875 | 20.75 | 22.583 |
32 | Gal-β-1,4-(Fuc-α-1,3)-GlcNAc-β-[Lewis X]–Sp | 30.375 | 65.5 | 35.625 | 43.833 |
33 | Neu5Ac-α-2,3-Gal-β-1,4-(Fuc-α-1,3)-GlcNAc-β-[sialyl Lewis X]-Sp | 20.875 | 38.625 | 26.25 | 28.583 |
34 | Neu5Ac-α-2,3-Gal-β-1,3-(Fuc-α-1,4)-GlcNAc-β-[sialyl Lewis A]-Sp | 15 | 16.875 | 12.875 | 14.916 |
35 | Neu5Gc-α-2,3-Gal-β-1,3-(Fuc-α-1,4)-GlcNAc-β- [sialyl Lewis A]-Sp | 13.125 | 11.75 | 2.25 | 9.0416 |
36 | Gal-α-1,4-Gal-β-1,3-GlcNAc-β-Sp | 12.625 | 46.375 | 38 | 32.333 |
37 | Gal-β-1,4-GlcNAc-β-1,3-Gal-β-1,4-Glc-β-[LNnT]-Sp | 193.75 | 183.625 | 133.375 | 170.25 |
38 | GlcA-β-1,4-GlcNAc-α-1,4-GlcA-β-Sp | 122.25 | 115.25 | 89.625 | 109.041 |
39 | GlcNAc-β-1,6-(Gal-β-1,3)-GalNAc-α-OSer-Sp4 | 34.625 | 44 | 8.25 | 28.958 |
40 | Neu5Ac-α-2,3Gal-β-1,4-(6S)GlcNAc-β-Sp | 28.25 | 36.25 | 55 | 39.833 |
41 | GalNAc-β-1,4-GlcNAc-β-Sp2 | 110.625 | 103.875 | 86 | 100.166 |
42 | Neu5Ac-α-2,8-Neu5Ac-α-2,3-Gal-β-1,4-Glc-β-Sp | 65.625 | 56.125 | 27.75 | 49.833 |
43 | Neu5Gc-α-2,8-Neu5Ac-α-2,3-Gal-β-1,4-Glc-β-Sp | 16.25 | 37.5 | 50.875 | 34.875 |
44 | GalNAc-α-1,3-(Fuc-α-1,2)-Gal-β-1,4-Glc-β-[blood A antigen tetrose]-Sp1 | 73.75 | 76.75 | 72.875 | 74.458 |
45 | GlcNAc-β-1,2-Man-α-Sp | 26.25 | 30 | 39.375 | 31.875 |
46 | Neu5Ac-α-2,3-Gal-β-Sp1 | 10.25 | 35.125 | 27 | 24.125 |
47 | Gal-β-1,3-GalNAc-β-1,3-Gal-β-Sp1 | 17.25 | 39.75 | 46.875 | 34.625 |
48 | Glc-α-1,2-Gal-α-Sp | 160.875 | 89.875 | 90.375 | 113.708 |
49 | Gal-β-1,4-(Fuc-α-1,3)-GlcNAc-β-1,3-Gal-β-Sp1 | 5.75 | 60.875 | 52.5 | 39.708 |
50 | Neu5Ac-α-2,3-Gal-β-1,4-(Fuc-α-1,3)-Glc-β-[3-sialyl-3-fucosyllactose/F-SL]-Sp1 | 28.625 | 74.875 | 57.75 | 53.75 |
51 | GlcNAc-β-1,4-GlcNAc-β-Sp1 | 57 | 68.125 | 58.125 | 61.083 |
52 | β-d-GlcA-Sp | 23 | 132.625 | 107.25 | 87.625 |
53 | Gal-β-1,4-(6S)GlcNAc-β-Sp | 101 | 156.875 | 103.125 | 120.333 |
54 | GlcNAc-α-1,3-(Glc-α-1,2-Glc-α-1,2)-Gal-α-1,3-Glc-α-Sp | 57.375 | 31 | 47.625 | 45.3333 |
55 | Gal-β-1,3-GalNAc-β-1,4-(Neu5Gc-α-2,3)-Gal-β-1,4-Glc-β-Sp1 | 6.875 | 98.125 | 95.875 | 66.958 |
56 | Sisomicin sulfate | 17.375 | 54.625 | 16.625 | 29.541 |
57 | GalNAc-α-1,3-(Fuc-α-1,2)-Gal-β-[blood A antigen trisaccharide]-Sp1 | 163.75 | 154.625 | 123.75 | 147.375 |
58 | Fuc-α-1,2-Gal-β-1,4-GlcNAc-β-[blood H antigen trisaccharide]-Sp1 | 68.125 | 94.875 | 62.625 | 75.208 |
59 | Gal-α-1,3-(Fuc-α-1,2)-Gal-β-[blood B antigen trisaccharide]-Sp1 | 124.875 | 139.5 | 119.125 | 127.833 |
60 | Fuc-α-1,2-Gal-β-1,3-GlcNAc-β-1,3-Gal-β-1,4-Glc-β-[LNFP I]-Sp1 | 52.5 | 84.25 | 104.375 | 80.375 |
61 | Fuc-α-1,2-Gal-β-1,4-Glc-β- [blood H antigen trisaccharide]-Sp1 | 48.75 | 33.25 | 36.25 | 39.416 |
62 | Gal-α-1,3-(Fuc-α-1,2)-Gal-β-1,4-Glc-β-[blood B antigen tetrasaccharide]-Sp1 | 18.75 | 25.75 | 27.375 | 23.958 |
63 | (Fuc-α-1,2)-Gal-β-1,4-(Fuc-α-1,3)-GlcNAc-β-[Lewis Y]-Sp1 | 1.25 | 23.625 | 8.875 | 11.25 |
64 | (Fuc-α-1,2)-Gal-β-1,3-(Fuc-α-1,4)-GlcNAc-β-[Lewis B]-Sp1 | 12.5 | 29.75 | 6.125 | 16.125 |
65 | Gal-β-1,3-(Fuc-α-1,4)-GlcNAc-β-1,3-Gal-β-1,4-(Fuc-α-1,4)-Glc-β-[Lewis A]-Sp1 | 19.75 | 42.625 | 9 | 23.791 |
66 | Gal-β-1,3-GalNAc-β-Sp1 | 14.625 | 18 | 30.125 | 20.916 |
67 | Gal-β-1,3-(Neu5Ac-α-2,6)-GalNAc-β-Sp | 3.25 | 4.5 | 14.75 | 7.5 |
68 | Neu5Ac-α-2,6-Gal-β-1,3-GalNAc-β-Sp | 42.125 | 27.625 | 39.125 | 36.291 |
69 | Neu5Ac-α-2,6-Gal-β-1,3-(Neu5Ac-α-2,6)-GalNAc-β-Sp | 53.875 | 56.625 | 45.5 | 52 |
70 | Neu5Ac-α-2,3-Gal-β-1,3-(Neu5Ac-α-2,6)-GalNAc-β-Sp | 70.25 | 93.25 | 21 | 61.5 |
71 | Neu5Ac-α-2,6-(Neu5Ac-α-2,3)-Gal-β-1,3-GalNAc-β-Sp | 4.625 | 5 | 1.25 | 3.625 |
72 | GalNAc-β-1,4-(Neu5Ac-α-2,3)-Gal-β-1,4-Glc-β-[GM2]-Sp | 4.5 | 37.25 | 75.625 | 39.125 |
73 | GalNAc-β-1,4-(Neu5Ac-α-2,8-Neu5Ac-α-2,3)-Gal-β-1,4-Glc-β-[GD2]-Sp | 31 | 49.75 | 17.625 | 32.791 |
74 | Gal-α-1,4-Gal-β-1,4-GlcNAc-β-Sp1 | 92 | 27.625 | 87 | 68.875 |
75 | β-d-Rha-Sp | 254.875 | 294.375 | 263 | 270.75 |
76 | Glc-α-1,4-Glc-β-Sp1 | 120.5 | 274.25 | 264.125 | 219.625 |
77 | Glc-α-1,6-Glc-α-1,4-Glc-β-Sp1 | 157.125 | 132.125 | 75.75 | 121.666 |
78 | Maltotriose-β-Sp1 | 52.5 | 100.5 | 26.875 | 59.958 |
79 | Glc-α-1,6-Glc-α-1,6-Glc-β-Sp1 | 11 | 90.875 | 60.375 | 54.083 |
80 | Maltotetraose-β-Sp1 | 89 | 71.5 | 63.5 | 74.666 |
81 | GlcNAc-α-1,4-GlcA-β-1,4-GlcNAc-α1,4-GlcA-β-Sp | 36.5 | 62.375 | 61.25 | 53.375 |
82 | Maltohexaose-β-Sp1 | 8.5 | 44.875 | 24 | 25.791 |
83 | Maltoheptaose-β-Sp1 | 28.625 | 47.5 | 28.875 | 35 |
84 | Acarbose-β-Sp1 | 39.5 | 75 | 60.25 | 58.25 |
85 | d-Pentamannuronic acid-β-Sp1 | 55 | 248.625 | 179.625 | 161.083 |
86 | l-Pentaguluronic acid-β-Sp1 | 50.25 | 105.75 | 103.625 | 86.541 |
87 | d-Cellose-β-Sp1 | 5 | 79.25 | 1.75 | 28.666 |
88 | Gal-α-1,3-Gal-β-Sp1 | 26 | 153.5 | 118.5 | 99.333 |
89 | β-1,4-xylotetrose-Sp1 | 42 | 122.25 | 94.125 | 86.125 |
90 | Chitin-trisaccharide-Sp1 | 31.875 | 21.75 | 24.125 | 25.916 |
91 | KDN-α-2,8-Neu5Ac-α-2,3-Gal-β-1,4-Glc-β-Sp | 153.375 | 132 | 41 | 108.791 |
92 | Neu5Ac-α-2,8-Neu5Gc-α-2,3-Gal-β-1,4- Glc-β-Sp | 21.25 | 40.25 | 23.75 | 28.416 |
93 | Neu5Ac-α-2,8-Neu5Ac-α-2,8-Neu5Ac-α-2,3-Gal-β-1,4-Glc-β-Sp3 | 15.875 | 68.125 | 40.125 | 41.375 |
94 | Neu5Ac-α-2,8-Neu5Ac-α-2,6-Gal-β-1,4-Glc-Sp5 | 12.75 | 43.5 | 4.25 | 20.166 |
95 | Gal-β-1,3-GalNAc-β-1,4-(Neu5Ac-α-2,3)-Gal-β-1,4-Glc-β-Sp1 | 21.5 | 105.5 | 54.125 | 60.375 |
96 | Gentamicin sulfate | 16.625 | 64.25 | 91 | 57.291 |
97 | Kanamycin sulfate | 30.5 | 66.75 | 142.75 | 80 |
98 | Geneticin disulfate salt (G418) | 12.25 | 36.5 | 37.75 | 28.833 |
99 | Neomycin trisulfate | 25.375 | 111.625 | 34.875 | 57.291 |
100 | SGP | 74.5 | 60.375 | 101.25 | 78.708 |
Glycan identities and mean fluorescence intensities (MFIs) of GFP-expressing P. aeruginosa PAO1 cells binding to 100 immobilized glycans. MFIs for each array were calculated as the average of the four data points from each glycan, spotted in quadruplicate on each array. A composite average MFI from the data across the 3 arrays (n = 12 for each glycan moiety) is shown in the final column. Positive glycan partners for P. aeruginosa were identified by the MFI as being at least 100 RFUs over background and significantly greater than the negative control; 28 glycans met these criteria.